34 reports

  • OCT 03, 2013: LUPIN LAUNCHES GENERIC ZYMAXID OPHTHALMIC SOLUTION IN THE US
  • AUG 28, 2013: LUPIN RECEIVES FDA APPROVAL FOR GATIFLOXACIN EYE DROPS

Bacterial Conjunctivitis - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis - Pipeline Review, H1 2018, provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline landscape. Bacterial...

  • Eye Disease
  • Ophthalmic Solution
  • United States
  • Litigation And Patent
  • InSite Vision Incorporated
  • OCT 03, 2013: LUPIN LAUNCHES GENERIC ZYMAXID OPHTHALMIC SOLUTION IN THE US
  • JUL 01, 2013: LUPIN GETS FDA TENTATIVE APPROVAL FOR GATIFLOXACIN EYE DROPS

Bacterial Conjunctivitis - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis - Pipeline Review, H2 2017, provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline landscape. Bacterial conjunctivitis...

  • Eye Disease
  • Ophthalmic Solution
  • United States
  • Litigation And Patent
  • InSite Vision Incorporated
  • NICOX RAISES USD31 MILLION IN PRIVATE PLACEMENT OF SHARES
  • APR 27, 2017: NICOX FIRST QUARTER 2017 BUSINESS UPDATE AND CASH POSITION

The company' s products include Vyzulta, a latanoprostene bunod ophthalmic solution; and Zerviate, a cetirizine ophthalmic solution.

  • Eye Disease
  • Ophthalmic Solution
  • United States
  • M&A
  • NicOx S.A.
  • 6.2.3 MUCOSTA OPHTHALMIC SOLUTION (REBAMIPIDE)
  • PRODUCT PROFILE - LIFITEGRAST

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which...

  • Ophthalmic Solution
  • Market Size
  • Allergan plc
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Clinical Trial profile. 41 Trial Title
  • Clinical Trial profile. 60 Trial Title

Allergic Conjunctivitis Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Allergic Conjunctivitis Global Clinical Trials Review, H1, 2017" provides an overview of Allergic Conjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on...

  • Ophthalmic Solution
  • OTC
  • Respiratory Treatment
  • World
  • Product Initiative
  • Clinical Trial profile. 465
  • Clinical Trial profile. 102

Conjunctivitis Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Conjunctivitis Global Clinical Trials Review, H1, 2017" provides an overview of Conjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Conjunctivitis. Report includes...

  • Clinical Trial
  • Ophthalmic Solution
  • Pharmaceutical
  • Therapy
  • World
  • PRT-2761 - DRUG PROFILE
  • EM-100 - DRUG PROFILE

Allergic Conjunctivitis - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Pipeline Review, H1 2018, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape. Allergic...

  • Ophthalmic Solution
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • 11.3 NOVARTIS AG
  • Joint Venture

The global topical drug delivery market is poised to reach USD 125.88 billion by 2021 from USD 92.40 billion in 2016, growing at a CAGR of 6.4% from 2016 to 2021. Major factors driving the growth of this market are the high incidence of burn injuries, rising geriatric population, and increasing incidence of diabetes. The topical drug...

  • Hospital
  • Ophthalmic Solution
  • North America
  • United States
  • Market Size
  • APR 27, 2017: NICOX FIRST QUARTER 2017 BUSINESS UPDATE AND CASH POSITION
  • MAR 31, 2017: NICOX: BUSINESS UPDATE AND 2016 FINANCIAL RESULTS

Subsequently, Nicox and VISUfarma agreed that Nicox would no longer be responsible for completing development and regulatory approval for AzaSite (azithromycin ophthalmic solution) ##% in Europe.

  • Medical Device
  • Ophthalmic Solution
  • United States
  • Company
  • NicOx S.A.
  • XENCOR INC
  • Allergic Conjunctivitis - Drug Profiles

The drug candidate is a topical ophthalmic solution containing high concentrations of hypochlorous acid as the active ingredient.

  • Ophthalmic Solution
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Clinical Trial profile. 27 Trial Title
  • Clinical Trial profile. 175 Trial Title

Conjunctivitis Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Conjunctivitis Global Clinical Trials Review, H2, 2016" provides an overview of Conjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Conjunctivitis. Report includes...

  • Allergy Drug
  • Eye Disease
  • Ophthalmic Solution
  • OTC
  • World

In July, Bausch + Lomb conducted a voluntary recall of a single lot of Murocel Methylcellulose Lubricant Ophthalmic Solution, USP ##%, within the US.

  • Ophthalmic Solution
  • Ophthalmology
  • United States
  • Company
  • Bausch & Lomb Incorporated
  • BAUSCH & LOMB INCORPORATED: RECENT DEVELOPMENTS
  • BAUSCH & LOMB INCORPORATED: RECENT DEVELOPMENTS

Bausch & Lomb Incorporated - Strategy, SWOT and Corporate Finance Report Summary Bausch & Lomb Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service...

  • Ophthalmic Solution
  • Ophthalmology
  • United States
  • Company
  • Bausch & Lomb Incorporated
  • KEY M&A
  • Vendor landscape

About Bacterial Conjunctivitis Drugs Bacterial conjunctivitis, which affects either one or both the eyes, is an extremely contagious eye condition wherein the conjunctiva is infected. Staphylococci, streptococci, gonococci, and Chlamydia are some of the causative agents of bacterial conjunctivitis. Extremely pathogenic bacteria such...

  • Ophthalmic Solution
  • Akorn, Inc.
  • Alcon, Inc.
  • Allergan plc
  • Bausch & Lomb Incorporated
  • Strengths
  • Scope of the report

About Conjunctivitis Conjunctivitis, also called pink eye or Madras eye, is an infection in or inflammation of the conjunctiva. It affects either one or both a person's eyes and can be the result of an allergy, bacteria, or a virus. Allergens such as smoke, pollen, dust mites, eye drops, cosmetics, and perfumes can lead to conjunctivitis....

  • Ophthalmic Solution
  • Ophthalmology
  • Akorn, Inc.
  • Alcon, Inc.
  • Allergan plc
  • BAUSCH & LOMB ENTERS INTO LICENSING AGREEMENT WITH PARAGON BIOTECK FOR PHENYLEPHRINE

The company' s products include Vyzulta, a latanoprostene bunod ophthalmic solution; and Zerviate, a cetirizine ophthalmic solution.

  • Ophthalmic Solution
  • Pharmaceutical
  • United States
  • M&A
  • Bausch & Lomb Incorporated
  • BAUSCH & LOMB ENTERS INTO LICENSING AGREEMENT WITH PARAGON BIOTECK FOR PHENYLEPHRINE

Phenylephrine Hydrochloride Ophthalmic Solution, USP ##. ##% and ##% is an alpha-## adrenergic receptor agonist used for dilation of the pupil due to its vasoconstrictor and mydriatic action.

  • Ophthalmic Solution
  • Ophthalmology
  • United States
  • M&A
  • Bausch & Lomb Incorporated
  • Implementing inorganic growth strategies Advancing its pipeline through increased investment in R&D
  • Vendor landscape

It is a polyvinyl alcohol ophthalmic solution, which consists of ##. ##% ocular lubricant sterile solution.

  • Ophthalmic Solution
  • Akorn, Inc.
  • Alcon, Inc.
  • Allergan plc
  • Bausch & Lomb Incorporated
  • 5.2.3 Mucosta ophthalmic solution (rebamipide)
  • Product Profile - Mucosta

Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially...

  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • 5.2.3 Mucosta ophthalmic solution (rebamipide)
  • Product Profile - Lifitegrast

Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially...

  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • 5.2.3 Mucosta ophthalmic solution (rebamipide)
  • Product Profile - Lifitegrast

Dry Eye Syndrome - Japan Drug Forecast and Market Analysis to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially...

  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • 5.2.3 Mucosta ophthalmic solution (rebamipide)
  • Product Profile - Tavilermide

Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially...

  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • 5.2.3 Mucosta ophthalmic solution (rebamipide)
  • Product Profile - Lifitegrast

Dry Eye Syndrome - 5EU Drug Forecast and Market Analysis to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially...

  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.

The company offers near vision solutions and develops ophthalmic medical devices.

  • Ophthalmic Solution
  • United States
  • Company
  • Market Segment
  • Hoya Corporation

For instance, the recent approval of Zerviate (cetirizine) for the treatment of allergic conjunctivitis in 2017 and Humira (adalimumab) and Xiidra (lifitegrast) in 2016 as ophthalmic solutions for the treatment of uveitis and dry eyes are expected to boost the market growth.

  • Ophthalmic Solution
  • OTC
  • Pharmaceutical
  • United States
  • Forecast

Thus they are known as one step peroxide solutions.

  • Ophthalmic Solution
  • Pharmaceutical
  • North America
  • Forecast
  • Valeant Pharmaceuticals International, Inc.

The company has started providing ophthalmic solutions like Zeiss Ophthalmic Data Management Solution, Zeiss Toric Solution & Zeiss Refractive Laser Solution.

  • Ophthalmic Solution
  • Abbott Medical Optics, Inc.
  • Alcon, Inc.
  • Carl Zeiss Meditec AG
  • Essilor group

The prominent features of this report are - ##.

  • Allergy Drug
  • Ophthalmic Solution
  • OTC
  • World
  • Product Initiative

Multipurpose solutions and one step peroxide solutions are covered under this segment.

  • Healthcare
  • Ophthalmic Solution
  • North America
  • United States
  • Alcon, Inc.
  • TRENDS

EYE CARE IN COLOMBIA Euromonitor International September 2016 Passport I LIST OF CONTENTS AND TABLES Passport II Passport ## EYE CARE IN COLOMBIA - CATEGORY ANALYSIS TRENDS Eye care sees an increase of ##% in current value terms in 2016, to reach Col$##. ## billion Laboratorios Alcon de Colomb

  • Ophthalmic Solution
  • OTC
  • Colombia
  • Demand